Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.30 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862744 | 0.87 | ALDH1A1 (0.34) | ALDH1A1TSHRNPC1GRIN2DGRIN3B | |
| SCHEMBL4862148 | 0.85 | NPC1 (0.30) | ALDH1A1NPC1 | |
| SCHEMBL6920723 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TSHRNPC1SLC22A2SLC47A1 | |
| SCHEMBL4862776 | 0.81 | ALDH1A1 (0.33) | ALDH1A1TSHRNPC1GRIN2DGRIN3B | |
| SCHEMBL15290898 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TSHR | |
| SCHEMBL7737331 | 0.77 | GRIN2D (0.48) | ALDH1A1TSHRNPC1GRIN2DGRIN3B | |
| SCHEMBL5901188 | 0.74 | ALDH1A1 (0.36) | ALDH1A1TSHRNPC1GRIN2DGRIN3B | |
| SCHEMBL28556200 | 0.74 | ALDH1A1 (0.36) | ALDH1A1TSHRNPC1GRIN2DGRIN3B | |
| SCHEMBL3680712 | 0.73 | TSHR (0.49) | ALDH1A1TSHRNPC1GRIN2DGRIN3B | |
| SCHEMBL4865804 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456311-B2 | Adamantane derivative, process for producing the same, and photosensitive material for photoresist | IDEMITSU KOSAN CO., LTD. (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080009647-A1 | Adamantane Derivative, Process for Producing the Same, and Photosensitive Material for Photoresist | IDEMITSU KOSAN CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1803708-A1 | ADAMANTANE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PHOTOSENSITIVE MATERIAL FOR PHOTORESIST | IDEMITSU KOSAN CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009647-A1 | Adamantane Derivative, Process for Producing the Same, and Photosensitive Material for Photoresist | LSS, C1S, DHPS | ALDH1A1 1544/4885TSHR 3738/4885NPC1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.